dexloxiglumide
Dexloxiglumide is a drug which acts as a cholecystokinin antagonist, selective for the CCKA subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome, dyspepsia, constipation and pancreatitis, and has had moderate success so far although trials are still ongoing. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2003 (NCT00220090)
Timeline
Indications
Mechanism of action
- Cholecystokinin A receptorANTAGONIST
Cholecystokinin A receptor antagonist
- CholecystokininINHIBITOR
CCK inhibitor
Chemistry & pharmacology
SMILES
CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1- Mol. weight
- 461.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDexloxiglumide ↗
- ChEMBLCHEMBL550781 ↗
Also known as
- cr 2017
- cr 2017
- dexloxiglumide
- dexloxiglumide
- dexloxiglumide
- dexloxiglumide
- dexloxiglumide
- dexloxiglumide
- d-loxiglumide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00303264 | Phase 2 | May 1, 2006 | Forest Laboratories |
| NCT00220090 | Phase 3 | Jul 1, 2003 | Rottapharm, University of Manchester |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forest Laboratories | For profit | 1 | 1 | 1 | 2006 |
| Rottapharm | For profit | 1 | 1 | 1 | 2003 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2003 |